Keywords: ralfinamide, enters, ph, iib/iii, study, nlbp, italy

Ralfinamide enters Ph IIb/III study in NLBP

Article | 01 April 2009

Print This

Italy's Newron Pharmaceuticals SpA has randomized the first patients to treatment in its first Phase IIb/III study of ralfinamide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in